Metastatic Malignant Neoplasm in the Brain Clinical Trial
Official title:
Pilot Study to Assess Heterogeneity of the Blood Brain Barrier in Patients With CNS Malignancy
This pilot research trial studies blood brain barrier differences in patients with brain tumors undergoing surgery. Studying samples of tissue and blood from patients with brain tumors in the laboratory may help doctors to understand how well drugs get into different parts of a brain tumor. This may help them to determine which types of drugs may be best for treating brain tumors.
PRIMARY OBJECTIVE: I. To define the heterogeneity of blood brain barrier (BBB) permeability by assessing drug distribution in a population of patients with central nervous system (CNS) malignancy. SECONDARY OBJECTIVE: I. Establish correlation of BBB permeability with radiographic appearance for study patients. CORRELATIVE RESEARCH OBJECTIVE: I. To utilize tumor samples to investigate mechanisms for BBB heterogeneity. OUTLINE: As part of pre-operative standard of care, patients receive levetiracetam by injection and cefazolin by injection. Patients are also offered lorazepam in the pre-operative area. At the time of surgery, patients undergo approximately 2 tissue biopsies from 3-4 tumor locations. This tissue is removed as part of the planned surgery, but it is also tested for research purposes. During surgery, a blood sample is collected every 20-30 minutes beginning at the time of skin incision until all of the research tumor samples have been removed. A minimum of 3 blood samples are collected up to a maximum of 12. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04062305 -
nTMS in Planning Stereotactic Radiosurgery in Patients With Brain Metastases in the Motor Cortex
|
N/A | |
| Recruiting |
NCT05388877 -
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
|
Phase 1 | |
| Active, not recruiting |
NCT02595905 -
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
|
Phase 2 | |
| Recruiting |
NCT03270059 -
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
|
Phase 2 | |
| Terminated |
NCT00096265 -
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT02858869 -
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
|
Phase 1 | |
| Active, not recruiting |
NCT04250545 -
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05341349 -
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases
|
Phase 1 | |
| Active, not recruiting |
NCT04114981 -
Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease
|
Phase 3 | |
| Recruiting |
NCT03741673 -
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
|
Phase 3 | |
| Completed |
NCT03680144 -
Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases
|
N/A | |
| Completed |
NCT02167204 -
18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors
|
N/A | |
| Recruiting |
NCT03750227 -
Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
|
Phase 3 | |
| Terminated |
NCT00659126 -
Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
|
Phase 2 | |
| Recruiting |
NCT03418961 -
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT02993146 -
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
|
Phase 1 | |
| Not yet recruiting |
NCT06328686 -
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases
|
Early Phase 1 | |
| Active, not recruiting |
NCT02589522 -
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
|
Phase 1 | |
| Recruiting |
NCT04804644 -
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
|
Phase 3 | |
| Withdrawn |
NCT03868423 -
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
|
Phase 2 |